Esophageal cancer other imaging findings

	Esophageal cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Esophageal cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Esophageal cancer other imaging findings On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Esophageal cancer other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Esophageal cancer other imaging findings
CDC on Esophageal cancer other imaging findings
Esophageal cancer other imaging findings in the news
Blogs on Esophageal cancer other imaging findings
Directions to Hospitals Treating Esophageal cancer
Risk calculators and risk factors for Esophageal cancer other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]

Overview

Other imaging studies for esophageal cancer include positive emission tomography scanning with 18-fluorodeoxyglucose (FDG-PET).

FDG-PET is a noninvasive staging modality that is more sensitive than CT or EUS for the detection of distant metastases.^[1]^[2]^[3]
In 20% of cases, management of esophageal cancer was changed after being scanned with FDG-PET.^[2]
FDG-PET siginificantly improves the detection of stage IV esophageal cancer.

↑ van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD (2008). "Staging investigations for oesophageal cancer: a meta-analysis". Br. J. Cancer. 98 (3): 547–57. doi:10.1038/sj.bjc.6604200. PMC 2243147. PMID 18212745.
↑ ^2.0 ^2.1 Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L (2000). "Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma". J. Clin. Oncol. 18 (18): 3202–10. doi:10.1200/JCO.2000.18.18.3202. PMID 10986052.
↑ Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA, Cooper JD (1997). "Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography". AJR Am J Roentgenol. 168 (2): 417–24. doi:10.2214/ajr.168.2.9016218. PMID 9016218.